• Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka
Recombinant Antibodies for Immunotherapy

Recombinant Antibodies for Immunotherapy

9780521887328
566,94 zł
510,24 zł Zniżka 56,70 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 510,24 zł
Ilość
Od 4 do 6 tygodni

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, arming mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.
Szczegóły produktu
97882
9780521887328
9780521887328

Opis

Rok wydania
2009
Numer wydania
1
Oprawa
twarda
Liczba stron
434
Wymiary (mm)
181.00 x 260.00
Waga (g)
1210
  • Part I. Introduction:: 1. Past, present and future of recombinant antibodies G. Winter; Part II. Generation and Screening of Antibody Libraries:: 2. Antibody libraries from na?ve V gene sources G. Beste and D. Lowe; 3. Antibodies from IgM libraries V. Molkenthin and S. Knackmuss; Part III. Transgenic Human Antibody Repertoires:: 4. The generation and screening of synthetic antibody libraries I. Klagge; 5. Therapeutic antibodies from xenoMouse transgenic mice A. Jakobovits; 6. Transgenic chimeric antibodies A. Murphy; Part IV. Humanised Antibodies:: 7. Humanization of recombinant antibodies J. Saldanha; 8. Immunogenicity assessment of antibody therapeutics P. Stas, J. Pletinckx, Y. Gansemans, and I. Lasters; 9. In vitro screening for antibody immunogenicity F. Carr and M. Baker; Part V. Antibody Effector Function:: 10. Mechanisms of tumour cell killing by therapeutic antibodies R. Stewart and C. Webster; 11. Optimization of Fc domains to enhance antibody therapeutics G. Lazar and A. Chamberlain; 12. Glycoengineered therapeutic antibodies P. Brünker, P. Sondermann, and P. Umana; Part VI. Arming Antibodies:: 13. Monoclonal antibodies for the delivery of cytotoxic drugs D. King; 14. Immunotherapy with radioimmune conjugates C. Kousparou and A. Epenetos; 15. Immunotherapeutic antibody fusion proteins N. Courtenay-Luck and D. Jones; Part VII. Antibody Fragments:: 16. Alternative antibody formats F. Le Gall and M. Little; 17. Single domain antibodies S. Muyldermans; 18. Engineering of non-CDR loops in immunoglobulin domains F. Rüker and G. Wozniak-Knopp; Part VIII. Antigen Binding Repertoires of Non-Immunoglobulin Proteins:: 19. Alternative antibody scaffolds A. Plueckthun; Part IX. Prolongation of Serum Half Life:: 20. Polymer fusions to increase antibody half lives:: PEGylation and other modifications S. Heywood and D. Humphreys; 21. Extending antibody half-lives with albumin J. Andersen and I. Sandlie; Part X. Current Therapeutic Antibodies and Novel Developments:: 22. A stem cell-based platform for the discovery and development of anti-tumor therapeutic antibodies to novel targets J. Mather, C. Fieger, T. Liang, K. King, J. Li, P. Young, C. Beltejar, B. Potts, M. Licea, and D. Loo; 23. Antibody directed enzyme prodrug therapy (ADEPT) H. Lowe, S. Sharma, and K. Bagshawe; 24. Immune privilege and tolerance - therapeutic antibody approaches D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H. Waldmann, and M. Rosenzweig; Part XI. Market Overview and Outlook:: 25. Antibody therapeutics:: business achievements and business outlook C. Bourrilly.
Komentarze (0)